MGC018 With or Without MGA012 in Advanced Solid Tumors

Exclusion Criteria

• •Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on MRI, CT or PET within 6 months, or history of leptomeningeal disease or cord compression at the time of enrollment.
• •Prior treatment with B7-H3 targeted agents for cancer.
• •Treatment with systemic cancer therapy, biologic agents, or anti-hormonal therapy (mCRPC) within 4 weeks, prior small molecule targeted or kinase inhibitors within 14 days or 5 half-lives, prior radioligand within 6 months
• •Clinically significant cardiovascular disease.
• •Clinically significant pulmonary compromise or requirement for supplemental oxygen.
• •History of clinically-significant cardiovascular disease, including but not limited to pericarditis or pericardial effusion.
• •Active viral (including confirmed or presumed COVID-19), bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration.
• •Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.
• •Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
• •Major trauma or major surgery within 4 weeks of first study drug administration.
• •Clinically significant venous insufficiency.
• •\> Grade 1 peripheral neuropathy.
• •Evidence of pleural effusion.
• •Evidence of ascites.
• •Serum testosterone \>50 ng/dl or \>1.7 nmol/L in mCRPC in Module A Cohort Expansion Phase